The outcome of NASH trials is forthcoming and provides direction for future targets, but most drugs focused on a single lipid or inflammatory target, e. g., ACC1 [31], PPARs and FXR (examples in Table E in S1 File), CCR2 [30] and CCR5 [30], or reduction in a chemotaxis protein, such as MCP-1 [30]. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.